Followers | 507 |
Posts | 10138 |
Boards Moderated | 0 |
Alias Born | 04/28/2014 |
Sunday, May 31, 2015 2:22:22 PM
bullish
## source: finance.yahoo.com
Fri, 29 May 2015 09:34:01 GMT ~ Affimed ASCO Data Demonstrate Consistent Potency of NKCell- Engaging Combination Therapy with Checkpoint Modulators
[at noodls] - FOR IMMEDIATE RELEASE Affimed ASCO Data Demonstrate Consistent Potency of NK- Cell-Engaging Combination Therapy with Checkpoint Modulators --Affimed's lead NK-cell engager AFM13 shows highly synergistic ...
read full: http://www.noodls.com/view/0540FFACD1E397FA384BF468BCD28DBAD60D59E4
*********************************************************
Fri, 29 May 2015 09:34:01 GMT ~ Affimed ASCO Data for the CD33/CD3-TandAb Program Demonstrate that CD33 and CD3 binding affinities correlate with potent T-cell activation and cytotoxicity
[at noodls] - FOR IMMEDIATE RELEASE -- TandAb platform enables reliable and rapid candidate selection -- Heidelberg, Germany, May 29, 2015 - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused ...
read full: http://www.noodls.com/view/830DAF67A8F086FEE3DF2921A4E835E8A151B78E
*********************************************************
Fri, 29 May 2015 09:16:00 GMT ~ 5:16 am Affimed Therapeutics' lead NK-cell engager AFM13 shows highly synergistic efficacy with PD-1 inhibitor
read full: http://finance.yahoo.com/news/inplay-briefing-com-055139997.html#afmd
*********************************************************
Fri, 29 May 2015 09:00:00 GMT ~ Affimed ASCO Data for the CD33/CD3-TandAb Program Demonstrate that CD33 and CD3 Binding Affinities Correlate with Potent T-cell Activation and Cytotoxicity
[GlobeNewswire] - HEIDELBERG, Germany -- Affimed N.V. , a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies based on its proprietary TandAb platform, today ...
read full: http://finance.yahoo.com/news/affimed-asco-data-cd33-cd3-090000884.html
*********************************************************
Fri, 29 May 2015 09:00:00 GMT ~ Affimed ASCO Data Demonstrate Consistent Potency of NK-Cell-Engaging Combination Therapy with Checkpoint Modulators
[GlobeNewswire] - HEIDELBERG, Germany -- Affimed N.V. , a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, today provided details on preclinical data ...
read full: http://finance.yahoo.com/news/affimed-asco-data-demonstrate-consistent-090000605.html
*********************************************************
$AFMD charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$AFMD company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/AFMD/company-info
Ticker: $AFMD
OTC Market Place: Not Available
CIK code: not found
Company name: Affimed N.V.
Incorporated In:
$AFMD share structure
## source: otcmarkets.com
Market Value: Not Available
Shares Outstanding: Not Available
Float: Not Available
Authorized Shares: Not Available
Par Value: Not Available
$AFMD extra dd links
Company name: Affimed N.V.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/AFMD/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/AFMD/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=AFMD+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=AFMD+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=AFMD+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/AFMD/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/AFMD/news - http://finance.yahoo.com/q/h?s=AFMD+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/AFMD/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/AFMD/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/AFMD/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/AFMD/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/AFMD/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/AFMD/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/AFMD/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/AFMD/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=AFMD+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/AFMD
DTCC (dtcc.com): http://search2.dtcc.com/?q=Affimed+N.V.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Affimed+N.V.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Affimed+N.V.&x=0&y=0
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/AFMD/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/AFMD
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/AFMD/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/AFMD/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/AFMD/sec-filings
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/AFMD/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/AFMD/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/AFMD/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/AFMD/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=AFMD&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=AFMD
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/AFMD/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=AFMD+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=AFMD+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=AFMD
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=AFMD
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=AFMD+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/AFMD/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=AFMD+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/AFMD.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=AFMD
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/AFMD/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/AFMD/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/AFMD/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/AFMD/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/AFMD
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/AFMD
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/AFMD:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=AFMD
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=AFMD
$AFMD DD Notes ~ http://www.ddnotesmaker.com/AFMD
Recent AFMD News
- Affimed Announces Acceptance of AFM24 Clinical Abstract at the 2024 Annual Meeting of the American Society of Clinical Oncology • GlobeNewswire Inc. • 04/24/2024 08:05:00 AM
- Affimed Reports 2023 Financial Results and Operational Progress • GlobeNewswire Inc. • 03/28/2024 10:30:00 AM
- Affimed To Report Full Year 2023 Financial Results & Corporate Update on March 28, 2024 • GlobeNewswire Inc. • 03/21/2024 10:30:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/11/2024 08:05:48 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/06/2024 11:34:50 AM
- Affimed Announces 1-for-10 Reverse Stock Split • GlobeNewswire Inc. • 03/06/2024 11:30:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/08/2024 09:45:56 PM
- Affimed Provides Clinical Response Update on AFM24-102 Trial in EGFR-wildtype Non-Small Cell Lung Cancer • GlobeNewswire Inc. • 01/08/2024 09:05:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/08/2024 01:11:55 PM
- Affimed Announces Leadership Change and Organizational Restructuring • GlobeNewswire Inc. • 01/08/2024 01:00:00 PM
- Affimed Announces Sale of Wholly-Owned Subsidiary AbCheck • GlobeNewswire Inc. • 01/03/2024 11:30:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/11/2023 11:10:55 AM
- Affimed Announces Positive Data for AFM24 in Combination with the PD-L1 Checkpoint Inhibitor Atezolizumab in Heavily Pre-treated EGFR-Wildtype Non-Small Cell Lung Cancer Patients • GlobeNewswire Inc. • 12/11/2023 11:02:00 AM
- Affimed Announces Updated Phase 1/2 Data from Acimtamig in Combination with Allogeneic NK in Hodgkin Lymphoma Patients Who Failed Prior Chemotherapy and Are Double-Refractory to Brentuximab Vedotin (BV) and Checkpoint Inhibitors (CPIs) • GlobeNewswire Inc. • 12/11/2023 11:00:00 AM
- Affimed to Host Investor Conference Call Highlighting Clinical Data for Acimtamig (AFM13) and AFM24 • GlobeNewswire Inc. • 12/04/2023 11:30:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/30/2023 12:00:57 PM
- Affimed Reports Third Quarter 2023 Financial Results and Highlights Operational Progress • GlobeNewswire Inc. • 11/14/2023 11:30:00 AM
- Affimed Announces Acimtamig as International Nonproprietary Name for AFM13 • GlobeNewswire Inc. • 11/09/2023 11:30:00 AM
- Affimed to Report Third Quarter 2023 Financial Results & Corporate Update on November 14, 2023 • GlobeNewswire Inc. • 11/07/2023 11:30:00 AM
- Affimed Presents Preclinical Data Showing that Addition of an Innate Cell Engager to NK and CAR-NK Cells Improves Tumor Cytotoxicity of Both Cell Types at the 38th Annual Meeting of the Society for Immunotherapy of Cancer • GlobeNewswire Inc. • 11/03/2023 04:05:00 PM
- Affimed Announces Oral Presentation of Phase 1/2 Data from AFM13 in Combination with Allogeneic NK Cells at the 2023 ASH Annual Meeting • GlobeNewswire Inc. • 11/02/2023 01:05:00 PM
- Affimed to Participate in Upcoming Investor Conferences • GlobeNewswire Inc. • 11/01/2023 10:30:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 10/04/2023 10:40:55 AM
- Affimed Announces Listing Transfer to Nasdaq Capital Markets • GlobeNewswire Inc. • 10/04/2023 10:30:00 AM
- Affimed Announces Acceptance of an Abstract Comparing NK Cells Redirected by Innate Cell Engagers and CAR-NK Cells for Poster Presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer • GlobeNewswire Inc. • 09/27/2023 01:05:00 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM